Cancer Stem and Progenitor-Like Cells as Pharmacological Targets in Breast Cancer Treatment

Cancer Stem and Progenitor-Like Cells as Pharmacological Targets in Breast Cancer Treatment

Show other versions (1)

The present review is focused on the current role of neoplastic stem and progenitor-like cells as primary targets in the pharmacotherapy of cancer as well as in the development of new anticancer drugs. We begin by summarizing the main characteristics of these tumor-initiating cells and key concepts...

Full description

Bibliographic Details
Main Authors: Valéria B. De Souza, André A. Schenka
Format: Article
Language:English
Published: SAGE Publishing 2015-01-01
Series:Breast Cancer: Basic and Clinical Research
Online Access:https://doi.org/10.4137/BCBCR.S29427
id doaj-22c558611f884439aac0fe17f3322f2d
record_format Article
spelling doaj-22c558611f884439aac0fe17f3322f2d2020-11-25T03:24:16ZengSAGE PublishingBreast Cancer: Basic and Clinical Research1178-22342015-01-019s210.4137/BCBCR.S29427Cancer Stem and Progenitor-Like Cells as Pharmacological Targets in Breast Cancer TreatmentValéria B. De Souza0André A. Schenka1Department of Anatomic Pathology, School of Medical Sciences, State University of Campinas (UNICAMP), São Paulo, Brazil.Department of Anatomic Pathology, School of Medical Sciences, State University of Campinas (UNICAMP), São Paulo, Brazil.The present review is focused on the current role of neoplastic stem and progenitor-like cells as primary targets in the pharmacotherapy of cancer as well as in the development of new anticancer drugs. We begin by summarizing the main characteristics of these tumor-initiating cells and key concepts that support their participation in therapeutic failure. In particular, we discuss the differences between the major carcinogenesis models (ie, clonal evolution vs cancer stem cell (CSC) model) with emphasis on breast cancer (given its importance to the study of CSCs) and their implications for the development of new treatment strategies. In addition, we describe the main ways to target these cells, including the main signaling pathways that are more activated or altered in CSCs. Finally, we provide a comprehensive compilation of the most recently tested drugs.https://doi.org/10.4137/BCBCR.S29427
collection DOAJ
language English
format Article
sources DOAJ
author Valéria B. De Souza
André A. Schenka
spellingShingle Valéria B. De Souza
André A. Schenka
Cancer Stem and Progenitor-Like Cells as Pharmacological Targets in Breast Cancer Treatment
Breast Cancer: Basic and Clinical Research
author_facet Valéria B. De Souza
André A. Schenka
author_sort Valéria B. De Souza
title Cancer Stem and Progenitor-Like Cells as Pharmacological Targets in Breast Cancer Treatment
title_short Cancer Stem and Progenitor-Like Cells as Pharmacological Targets in Breast Cancer Treatment
title_full Cancer Stem and Progenitor-Like Cells as Pharmacological Targets in Breast Cancer Treatment
title_fullStr Cancer Stem and Progenitor-Like Cells as Pharmacological Targets in Breast Cancer Treatment
title_full_unstemmed Cancer Stem and Progenitor-Like Cells as Pharmacological Targets in Breast Cancer Treatment
title_sort cancer stem and progenitor-like cells as pharmacological targets in breast cancer treatment
publisher SAGE Publishing
series Breast Cancer: Basic and Clinical Research
issn 1178-2234
publishDate 2015-01-01
description The present review is focused on the current role of neoplastic stem and progenitor-like cells as primary targets in the pharmacotherapy of cancer as well as in the development of new anticancer drugs. We begin by summarizing the main characteristics of these tumor-initiating cells and key concepts that support their participation in therapeutic failure. In particular, we discuss the differences between the major carcinogenesis models (ie, clonal evolution vs cancer stem cell (CSC) model) with emphasis on breast cancer (given its importance to the study of CSCs) and their implications for the development of new treatment strategies. In addition, we describe the main ways to target these cells, including the main signaling pathways that are more activated or altered in CSCs. Finally, we provide a comprehensive compilation of the most recently tested drugs.
url https://doi.org/10.4137/BCBCR.S29427
work_keys_str_mv AT valeriabdesouza cancerstemandprogenitorlikecellsaspharmacologicaltargetsinbreastcancertreatment
AT andreaschenka cancerstemandprogenitorlikecellsaspharmacologicaltargetsinbreastcancertreatment
_version_ 1724602444043780096

Similar Items